Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

NKTR-118 Currently in Phase 1 Clinical Development for the Treatment of

Opioid Bowel Dysfunction

SAN CARLOS, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented positive results this week from Phase 1 and preclinical studies of NKTR-118 (oral PEG-naloxol) at the American Academy of Pain Management (AAPM) meeting in Las Vegas, Nevada. NKTR-118 is Nektar's proprietary oral therapy being studied for its potential to treat patients suffering from opioid-bowel dysfunction (OBD), including opioid-induced constipation (OIC).

Data from a single-dose, proof-of-principle Phase 1 trial on NKTR-118 demonstrate that the drug antagonized the morphine-induced delay in gastrointestinal (GI) transit time without reversing the central opioid effect as measured by pupillometry. Further, the study shows that the drug was well-tolerated at single, oral doses up to 1,000 mg. Data from this study were also presented earlier this month at the American College of Clinical Pharmacology meeting in San Francisco, California.

In preclinical studies presented at AAPM this week, oral NKTR-118 improved GI transit time in an animal model of morphine-induced constipation, while maintaining a substantial analgesic effect. In addition, NKTR-118 demonstrated significantly lower brain permeation than naloxone.

"These positive study results for NKTR-118 show that the drug offers potential for treating opioid-induced constipation, a serious and debilitating side effect of opioid therapy," said Tim Riley, Ph.D. Vice President of PEGylation Research at Nektar. "This application of Nektar's PEGylation technology to reduce blood-brain barrier penetration of a small molecule d
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...e-USNewswire/ -- Older adults who exercise regular...r number of small blood vessels in the brain, acco...eting of the Radiological Society of North America...University of North Carolina ( UNC) - Chapel Hill...ults who exercise to brain scans of those who do n...
(Date:11/26/2008)...USNewswire/ -- Children whose eyes are misaligned ...isk of developing mental illness by early adulthoo...ublished this month in Pediatrics , the official j... , The retrospective study examined the medica...ned eyes) and compared them with records of childr...
(Date:11/25/2008)...t expanding statin use broadly in wake of AHA-pres... JUPITER, a clinical trial suggest... of healthy patients with elevated CRP, should not...rding to a national poll directed at health profes...online poll conducted by medical news site MedPage...
(Date:11/25/2008)...ll/ -- CardioVascular,BioTherapeutics, Inc. (OTC ...,dosed the first patient in North America (NA) as...at patients with severe coronary heart disease. Th...ry heart Disease) trial will include,four randomi...roximately 120,patients with severe coronary hear...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Perrigo Announces Approval for Rx Cetirizine Syrup 22381 1Perrigo Announces Approval for Rx Cetirizine Syrup 22381 2World Vision Responding to Record Flooding in Midwest 22379 1World Vision Responding to Record Flooding in Midwest 22379 2Herpes Suppression May Not Prevent HIV Infection 22376 1Herpes Suppression May Not Prevent HIV Infection 22376 2NCPA Statement Endorsing H R 6252 and S 3144 22371 1NCPA Statement Endorsing H R 6252 and S 3144 22371 2
...SINESS WIRE)--Apr 26, 2007 - Northfield,Laboratori...ntract,research organization has informed the Comp...ivotal Phase III trauma trial with,PolyHeme(R), th...,red cell substitute, will not be complete until M...boratories Inc. is a leader in developing an,oxyge...
...: 0in 0in 0pt; TEXT-ALIGN: left; tab-stops: 0in",a...ab-stops: list .5in; mso-list: l1 level1 lfo2">, <...othic MT,; mso-bidi-font-weight: bold">,Independen... adding,Diovan to conventional therapy , , , ,<...in; mso-list: l1 level1 lfo2">, <span style=,"FONT...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 8Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 9Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 10Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 11Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 12
(Date:12/1/2008)...wire-USNewswire/ -- The Food Allergy & Anaphyl... Ph.D., as its new CEO, replacing Founder Anne Mun...er brings to FAAN extensive knowledge of anaphylax... For the past six years, as Senior Director of Mar...lanning for all Dey Pharmaceutical products, inclu...
(Date:12/1/2008)...ective against plantar fasciitis, researchers say ... Italian researchers say they,ve developed a fast,... foot condition known as plantar fasciitis. , U...njections guided by ultrasound, the researchers sa...e in tackling a condition that afflicts about one ...
(Date:12/1/2008)...ewswire-USNewswire/ -- Today, more than 740 childr...die each day due to HIV/AIDS. , , Decemb...reach to help people worldwide understand the impa... 2008 is You Can Make a Difference and the foc...o talk about HIV as well as helping dispel the myt...
(Date:12/1/2008)...USNewswire/ -- Condell Health Network, parent corp...tal in Libertyville - after voluntarily disclosing...ayments - has agreed without litigation to pay the...n as a result of filing false claims for reimburse...ey for the Northern District of Illinois. Condell...
Breaking Medicine News(10 mins):Health News:FAAN Names New CEO 2Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2Health News:Condell Health Network and Medical Center to Pay $36 Million Settlement After Self-Reporting Possible Health-Care Fraud 2
...ne replacement therapy (HRT) does not reduce the r... existing coronary artery disease (CAD). In the PH...searchers randomized 255 postmenopausal women with...ery disease to receive either transdermal HRT--17-...
...ajpayee, the Prime Minister of India has successfu...hittaranjan Ranawat at the Breach Candy Hospital i...10 a.m., was completed by 11.15 a.m. and went on v...t a press briefing. ``He (Mr. Vajpayee) was awake ...
...e first time have found a way for the survival of ... breakthrough a Massachusetts scientists who engi... endangered animal (Asian Gaur) and successfully i...he clone. The scientific journal Cloning has repo...
... an ever-growing menace on the Internet. Now a mil...500 health related web-sites that are such havens ...ideline for surfers to be weary of tall claims mad...formation can be accessed on http://www.ratbags.co...
Other Medicine News:
...ntains 20 titanium clips in the ML and M sizes, an...e designed for introduction and use through all ap...arger sized trocar sleeves with the use of a conve...lier through the trocar sleeve, press the loading ...
...sing male/female interlocking features. This desig...mproved hemostasis., ,By comparison, The Reflex&r...allowing for maximum visibility for precise clip p...direct drive clip feeding system with an audible f...
Insert only, Pilling-Weck small clip size
Insert only, Ethicon, medium clip size
Medicine Products: